ULUlrich Lücking

Ulrich Lücking

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ulrich Lücking has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Gerhard Siemeister

    Corporate Research Oncology, Schering AG, 13342 Berlin, Germany

    1 shared publication
  • Hans Briem

    CDCC/Computational Chemistry, Research Center Europe, Schering AG, 13342 Berlin, Germany

    1 shared publication
  • Martin Krüger

    Medicinal Chemistry, Research Center Europe, Schering AG, 13342 Berlin, Germany, Fax: (+49) 30-468-18170

    1 shared publication
  • Martina Schäfer

    ET/Structural Biology, Research Center Europe, Schering AG, 13342 Berlin, Germany

    1 shared publication
  • Philip Lienau

    CDCC/Research Pharmacokinetics, Research Center Europe, Schering AG, 13342 Berlin, Germany

    1 shared publication
  • Rolf Jautelat

    Medicinal Chemistry, Research Center Europe, Schering AG, 13342 Berlin, Germany, Fax: (+49) 30-468-18170

    1 shared publication

Latest Publications

  • Macrocyclic Aminopyrimidines as Multitarget CDK and VEGF‐R Inhibitors with Potent Antiproliferative Activities

    by Ulrich Lücking, Gerhard Siemeister, Martina Schäfer, Hans Briem, Martin Krüger, Philip Lienau, Rolf Jautelat

    X‐ray structures from CDK2–aminopyrimidine inhibitor complexes led to the idea to stabilize the active conformation of aminopyrimidine inhibitors by incorporating the recognition site into a macrocyclic framework. A modular synthesis approach that relies on a new late‐stage macrocyclization protocol that enables fast and efficient synthesis of macrocyclic aminopyrimidines was developed. A set of structurally diverse derivatives was prepared. Macrocyclic aminopyrimidines were shown to be multitarget inhibitors of CDK1/2 and VEGF‐RTKs. In addition, potent antiproliferative activities toward various human tumor cells and a human tumor xenograft model were demonstrated.